{"schema_version":"1","generated_at":"2026-10-29T21:50:57.336Z","data_as_of":null,"url":"https://www.findmykol.com/kol/uroosa-ibrahim","json_url":"https://www.findmykol.com/kol/uroosa-ibrahim/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"uroosa-ibrahim","name":"Uroosa Ibrahim","credential":"MB, BS","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Mount Sinai Hospital","institution_url":"https://www.findmykol.com/institution/icahn-school-of-medicine-at-mount-sinai","city":"New York","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1235494204","orcid":"0000-0003-0088-5438","openalex":"A5024808138"},"summary":"Uroosa Ibrahim is an Oncology physician affiliated with Mount Sinai Hospital. OpenAlex indexes 83 publications with 538 citations (h-index 13).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":83,"cited_by_count":538,"h_index":13,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":7,"program_years":{"first":2021,"last":null},"rows_total":10,"shown":3,"withheld":7,"rows":[{"payer":"Autolus Inc","program_year":2025,"amount_usd":8212,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1235494204"},{"payer":"Genetix Biotherapeutics Inc","program_year":2025,"amount_usd":5379.62,"payment_count":10,"source_url":"https://openpaymentsdata.cms.gov/search?query=1235494204"},{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":96.67,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1235494204"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1235494204","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Dermatology","share_pct":27.2,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":27.2,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":25.7,"classes_total":4,"classes":[{"class":"Bile Acid","setting":"prescribed","share_pct":8.6,"drugs":[{"name":"Ursodiol","share_pct":100}],"max_beneficiaries":null},{"class":"H2 blocker","setting":"prescribed","share_pct":7.1,"drugs":[{"name":"Famotidine","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":18.7,"classes_total":3,"classes":[{"class":"Short-acting sulfonamides","setting":"prescribed","share_pct":9.7,"drugs":[{"name":"Sulfamethoxazole-Trimethoprim","share_pct":100}],"max_beneficiaries":null},{"class":"Penicillin-class Antibacterial","setting":"prescribed","share_pct":4.5,"drugs":[{"name":"Penicillin V Potassium","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation","year":2025,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.jtct.2025.09.048","status":"verified"},{"title":"SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study","year":2024,"journal":"Clinical Infectious Diseases","source_url":"https://doi.org/10.1093/cid/ciae291","status":"verified"},{"title":"Dynamics of cytomegalovirus‐specific T‐cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study","year":2024,"journal":"Transplant Infectious Disease","source_url":"https://doi.org/10.1111/tid.14290","status":"verified"},{"title":"SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)","year":2024,"journal":"medRxiv","source_url":"https://doi.org/10.1101/2024.01.24.24301058","status":"verified"},{"title":"<scp>Real‐world</scp> evidence of the safety and survival with <scp>CD19 CAR‐T</scp> cell therapy for relapsed/refractory solid organ <scp>transplant‐related PTLD</scp>","year":2023,"journal":"British Journal of Haematology","source_url":"https://doi.org/10.1111/bjh.18828","status":"verified"}],"source":"works"},"contact":{"address_1":"10 E 102ND ST","city":"New York","state":"NY","zip":"100296030","phone":"212-241-6756","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1235494204","source":"identity"},"similar":[{"name":"Daniel J. Drucker","slug":"daniel-drucker","institution":"Mount Sinai Hospital","url":"https://www.findmykol.com/kol/daniel-drucker","json_url":"https://www.findmykol.com/kol/daniel-drucker/profile.json"},{"name":"Karyn Goodman","slug":"karyn-goodman","institution":"Mount Sinai Hospital","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/karyn-goodman","json_url":"https://www.findmykol.com/kol/karyn-goodman/profile.json"},{"name":"Edward Wolin","slug":"edward-wolin","institution":"Mount Sinai Hospital","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/edward-wolin","json_url":"https://www.findmykol.com/kol/edward-wolin/profile.json"},{"name":"Joshua Zeichner","slug":"joshua-zeichner","institution":"Mount Sinai Hospital","specialty":"Dermatology","url":"https://www.findmykol.com/kol/joshua-zeichner","json_url":"https://www.findmykol.com/kol/joshua-zeichner/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":7,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2020-08-05","provider_certified":"2020-08-05","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}